1-6 of 6
Brendan Hodkinson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Earlier use of ciltacabtagene autoleucel (cilta-cel) is associated with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study

Free
Samir Parekh, Katherine Li, Niels W.C.J. Van De Donk, Yi Lin, Thomas Martin, Siyu Han, Rocio Montes De Oca, Mahipal Suraneni, Michael Gormley, Brendan Hodkinson, Jinzhou Yuan, Feng Wang, Ashwini Kumar, Da Yin, Denis Smirnov, Jaymala Patel, Nikoletta Lendvai, Deepu Madduri, Jieqing Zhu, Mythili Koneru, Nitin Patel, Dong Geng, Vicki Plaks, Simon Harrison
Journal: Blood
Blood (2025) 146 (Supplement 1): 92.
https://doi.org/10.1182/blood-2025-92
Published: 2025
Journal Articles

Dose and BTK occupancy relationship in the prospective Phase 2 TAILOR study: Exploratory end point analysis of the ibrutinib monotherapy cohorts in patients with previously untreated chronic lymphocytic leukemia

Free
Jacqueline Barrientos, Michael Doubek, Zsolt Lazar, Andrea Visentin, Javier de la Serna, Luca Laurenti, Alessandro Sanna, Laszlo Rejto, Lucrecia Yanez San Segundo, Paolo Sportoletti, Carl Gray, CelesteAnn Bremer, Aziz Ouerdani, Nicoline Treijtel, Brendan Hodkinson, John Loffredo, Claire Kavanagh, Sowmya Srikanthan, Ping Xu, Erin Franceschini, Christopher Abbazio, Brooke Patterson, Boo Messahel, Wasiulla Khan, Jan Burger, Lori Parisi, Mark Wildgust, Paolo Ghia, Jeff Sharman
Journal: Blood
Blood (2025) 146 (Supplement 1): 3301.
https://doi.org/10.1182/blood-2025-3301
Published: 2025
Journal Articles

First-line ibrutinib + venetoclax shows benefit across genomic subgroups in patients with chronic lymphocytic leukemia (CLL): Results from Phase 2 captivate study and Phase 3 glow study

Free
Leo Cheung, Shiquan Wu, Brendan Hodkinson, Constantine Tam, William Wierda, Paolo Ghia, Anita Szoke, Edith Szafer Glusman
Journal: Blood
Blood (2025) 146 (Supplement 1): 5672.
https://doi.org/10.1182/blood-2025-5672
Published: 2025
Journal Articles

Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and TP53 mutation status

Available to Purchase
Clinical Trials & Observations
Ciara L. Freeman, Srimathi Srinivasan, Brendan Hodkinson, Sanjay Deshpande, Todd Henninger, Merrill Boyle, Michael L. Wang, Martin Dreyling, David W. Scott
Journal: Blood
Blood (2025) 145 (25): 3052–3056.
https://doi.org/10.1182/blood.2024026003
Published: 2025
Includes: Supplemental data
Journal Articles

Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial

Free
Peter Johnson, MDFRCP, Sriram Balasubramanian, Brendan Hodkinson, Michael Schaffer, Lori Parisi, S. Martin Shreeve, Steven Sun, Jessica Vermeulen, Laurie H Sehn, MD, Louis Staudt, Anas Younes, MD, Wyndham Wilson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 354.
https://doi.org/10.1182/blood-2019-124443
Published: 2019
Journal Articles

Identification of a Genetic Signature Enriching for Response to Ibrutinib in Relapsed/Refractory Follicular Lymphoma in the Dawn Phase 2 Trial

Free
Sriram Balasubramanian, Brendan Hodkinson, Stephen J. Schuster, MD, Nathan H. Fowler, MD, Judith Trotman, Georg Hess, Bruce Cheson, MD, Michael Schaffer, PhD, Shean-Sheng Wang, Sanjay Deshpande, Jessica Vermeulen, Gilles Salles, MD PhD, Ajay K. Gopal, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4147.
https://doi.org/10.1182/blood-2018-99-116472
Published: 2018